Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06887218 | 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 27, 2025 |
| clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06856187 | Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL) | recruiting | Phase 2 | 119 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07095439 | Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients | recruiting | Phase 2 | 38 | Ain Shams UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085169 | Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC | recruiting | Phase 2 | 50 | Ruijin HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT05571644 | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer(OPTICAL-2) | recruiting | Phase 2 | 143 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06873763 | Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 52 | STCube, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06630624 | Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM(INJECTABL-II) | recruiting | Phase 1 / Phase 2 | 120 | M.R. MeijerinkOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07047560 | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05310643 | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC(NIPIRESCUE) | recruiting | Phase 2 | 30 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05775146 | SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases | recruiting | Phase 2 | 24 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06885385 | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | recruiting | Phase 2 | 60 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05771181 | Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05908643 | A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 16 | Neogap Therapeutics ABINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06991465 | Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)(Hypo-OPRA) | recruiting | Phase 2 | 35 | Neil KopekOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05870800 | Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER(NICER) | recruiting | Phase 2 | 28 | Baylor College of MedicineOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06979908 | A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 46 | The First Hospital of Jilin UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06980532 | Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 42 | Liu HuangOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03401294 | Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.(CONVERSION) | recruiting | Phase 2 | 32 | University of SaskatchewanOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06949982 | Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes(x-МАР) | recruiting | Phase 2 | 60 | Sergey Orlov, MDOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05965531 | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy(TASLARC) | recruiting | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06923345 | Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) | recruiting | Phase 2 | 80 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06718543 | Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer(TRIUNITE-03) | recruiting | Phase 2 | 100 | fan liOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06888843 | Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.(AHTCRR-1) | recruiting | Phase 2 | 160 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06521866 | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer | recruiting | Phase 2 | 208 | Fudan UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06698757 | Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 96 | Yugui LianOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05093907 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 27 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03957902 | Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer | recruiting | Phase 2 | 60 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06763029 | Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer(VICPROIRI) | recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06840665 | MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06225843 | Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis(EGIA-003) | recruiting | Phase 2 | 17 | Alethia BiotherapeuticsINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06812728 | Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients | recruiting | Phase 2 | 100 | Menoufia UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06640166 | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.(ECLYPse) | recruiting | Phase 2 | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06802666 | Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2025source: clinicaltrials